Optus Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Optus Pharmaceutical makes prescription and over-the-counter eye drops, including preservative-free single-use vials, used to treat dry eye, glaucoma, and allergic conditions.
Listed on KOSDAQ, Korea's tech and small-cap board, it supplies hospitals and clinics directly and also manufactures eye drops on behalf of other pharmaceutical companies under contract development and manufacturing arrangements. Its business spans four segments: a prescription ophthalmology unit, a contract manufacturing unit, an export-focused global unit, and a consumer eye-care brand called OUE&.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates its own production facility in the Osong Life Science Industrial Complex in Chungcheongbuk-do and a central research institute in Suwon, giving it in-house manufacturing and R&D capabilities.
Optus Pharmaceutical in five facts
What does Optus Pharmaceutical do?
Optus Pharmaceutical makes prescription and over-the-counter eye drops, including preservative-free single-use vials, used to treat dry eye, glaucoma, and allergic conditions.
Where is Optus Pharmaceutical listed and in which sector?
Optus Pharmaceutical (Korean name: 옵투스제약) trades under KRX code 131030 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Optus Pharmaceutical?
Its market capitalisation was US$79.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Optus Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Optus Pharmaceutical reported revenue of US$65.8M, operating profit of US$6.7M and net income of US$8.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 6.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.